FDA Accepts Supplemental Application for OPDIVO QVANTIG by Bristol-Myers Squibb
The FDA has accepted a supplemental application for OPDIVO QVANTIG, which includes nivolumab and hyaluronidase-NVHY.
Therapeutic Area
Therapeutic area intelligence for Checkpoint Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.